Modulation of peripheral μ-opioid analgesia by σ1 receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 1, 2014, Pages 32-45

  Sánchez Fernández, Cristina ^a,b   Montilla García, Ángeles ^a   González Cano, Rafael ^a,b   Nieto, Francisco Rafael ^a,b   Romero, Lucía ^a   Artacho Cordón, Antonia ^a   Montes, Rosa ^b   Fernández Pastor, Begoña ^c   Merlos, Manuel ^c   Baeyens, José Manuel ^a,b   Entrena, José Manuel ^b   Cobos, Enrique José ^a,b  

^a Departments of Pharmacology   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c Drug Discovery and Preclinical Development   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; FENTANYL CITRATE; LOPERAMIDE; MORPHINE; OXYCODONE; SIGMA 1 OPIATE RECEPTOR; TRAMADOL;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEMALE; GASTROINTESTINAL TRANSIT; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

ANALGESICS, OPIOID; ANIMALS; CONSTIPATION; FEMALE; GANGLIA, SPINAL; MICE; MICE, KNOCKOUT; PAIN MEASUREMENT; RECEPTORS, OPIOID, MU; RECEPTORS, SIGMA;

EID: 84890502351     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.208272     Document Type: Article

References (57)

1. Al-Hasani R and Bruchas MR (2011) Molecular mechanisms of opioid receptordependent signaling and behavior. Anesthesiology 115:1363-1381.
2. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, and Vallejo R (2008) Opioid complications and side effects. Pain Physician 11(2, Suppl)S105-S120.
3. Bigliardi-Qi M, Sumanovski LT, Büchner S, Rufli T, and Bigliardi PL (2004) Muopiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology 209:183-189.
4. Cendán CM, Pujalte JM, Portillo-Salido E, and Baeyens JM (2005) Antinociceptive effects of haloperidol and its metabolites in the formalin test in mice. Psychopharmacology (Berl) 182:485-493.
5. Chien CC and Pasternak GW (1993) Functional antagonism of morphine analgesia by (1)-pentazocine: evidence for an anti-opioid sigma 1 system. Eur J Pharmacol 250:R7-R8.
6. Chien CC and Pasternak GW (1994) Selective antagonism of opioid analgesia by a sigma system. J Pharmacol Exp Ther 271:1583-1590.
7. Cobos EJ, Baeyens JM, and Del Pozo E (2005) Phenytoin differentially modulates the affinity of agonist and antagonist ligands for sigma 1 receptors of guinea pig brain. Synapse 55:192-195.
8. Cobos EJ, del Pozo E, and Baeyens JM (2007) Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells. J Neurochem 102:812-825.
9. Cobos EJ, Entrena JM, Nieto FR, Cendán CM, and Del Pozo E (2008) Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol 6:344-366.
10. Cobos EJ, Lucena G, Baeyens JM, and Del Pozo E (2006) Differences in the allosteric modulation by phenytoin of the binding properties of the sigma1 ligands [3H](1)-pentazocine and [3H]NE-100. Synapse 59:152-161.
11. Craft RM, Henley SR, Haaseth RC, Hruby VJ, and Porreca F (1995) Opioid antinociception in a rat model of visceral pain: systemic versus local drug administration. J Pharmacol Exp Ther 275:1535-1542.
12. de la Puente B, Nadal X, Portillo-Salido E, Sánchez-Arroyos R, Ovalle S, Palacios G, Muro A, Romero L, Entrena JM, and Baeyens JM, et al. (2009) Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain 145:294-303.
13. Dhingra L, Shuk E, Grossman B, Strada A, Wald E, Portenoy A, Knotkova H, and Portenoy R (2013) A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med 27:447-456.
14. Díaz JL, Zamanillo D, Corbera J, Baeyens JM, Maldonado R, Pericàs MA, Vela JM, and Torrens A (2009) Selective sigma-1 (sigma1) receptor antagonists: emerging target for the treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 9: 172-183.
15. Entrena JM, Cobos EJ, Nieto FR, Cendán CM, Baeyens JM, and Del Pozo E (2009a) Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors. Psychopharmacology (Berl) 205:21-33.
16. Entrena JM, Cobos EJ, Nieto FR, Cendán CM, Gris G, Del Pozo E, Zamanillo D, and Baeyens JM (2009b) Sigma-1 receptors are essential for capsaicin-induced mechanical hypersensitivity: studies with selective sigma-1 ligands and sigma-1 knockout mice. Pain 143:252-261.
17. Gallelli L, Colosimo M, Tolotta GA, Falcone D, Luberto L, Curto LS, Rende P, Mazzei F, Marigliano NM, and De Sarro G, et al. (2010) Prospective randomized doubleblind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. Eur J Clin Pharmacol 66:137-144.
18. Greenwood-Van Meerveld B and Standifer KM (2008) Methylnaltrexone in the treatment of opioid-induced constipation. Clin Exp Gastroenterol 1:49-58.
19. Hayashi T and Su TP (2004) Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 18:269-284.
20. Joshi SK, Mikusa JP, Weaver B, and Honore P (2008) Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert centrally mediated antinociception in the rat cyclophosphamide cystitis model of visceral pain. J Pain 9:146-156.
21. Kayser V, Lee SH, and Guilbaud G (1995) Evidence for a peripheral component in the enhanced antinociceptive effect of a low dose of systemic morphine in rats with peripheral mononeuropathy. Neuroscience 64:537-545.
22. Khalefa BI, Shaqura M, Al-Khrasani M, Fürst S, Mousa SA, and Schäfer M (2012) Relative contributions of peripheral versus supraspinal or spinal opioid receptors to the antinociception of systemic opioids. Eur J Pain 16:690-705.
23. Kim FJ, Kovalyshyn I, Burgman M, Neilan C, Chien CC, and Pasternak GW (2010) Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding. Mol Pharmacol 77: 695-703.
24. King M, Pan YX, Mei J, Chang A, Xu J, and Pasternak GW (1997) Enhanced kappaopioid receptor-mediated analgesia by antisense targeting the sigma1 receptor. Eur J Pharmacol 331:R5-R6.
25. Kuraishi Y, Hirota N, Satoh M, and Takagi H (1985) Antinociceptive effects of intrathecal opioids, noradrenaline and serotonin in rats: mechanical and thermal algesic tests. Brain Res 326:168-171.
26. Layer P and Andresen V (2010) Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea. Aliment Pharmacol Ther 31:1155-1164.
27. Marrazzo A, Cobos EJ, Parenti C, Aricò G, Marrazzo G, Ronsisvalle S, Pasquinucci L, Prezzavento O, Colabufo NA, and Contino M, et al. (2011) Novel potent and selective s ligands: evaluation of their agonist and antagonist properties. J Med Chem 54:3669-3673.
28. Marrazzo A, Parenti C, Scavo V, Ronsisvalle S, Scoto GM, and Ronsisvalle G (2006) In vivo evaluation of (1)-MR200 as a new selective sigma ligand modulating MOP, DOP and KOP supraspinal analgesia. Life Sci 78:2449-2453.
29. Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong DD, and De Costa BR (1995) Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol 280:301-310.
30. Mei J and Pasternak GW (2002) s1 receptor modulation of opioid analgesia in the mouse. J Pharmacol Exp Ther 300:1070-1074.
31. Mei J and Pasternak GW (2007) Modulation of brainstem opiate analgesia in the rat by s 1 receptors: a microinjection study. J Pharmacol Exp Ther 322:1278-1285.
32. Menéndez L, Lastra A, Meana A, Hidalgo A, and Baamonde A (2005) Analgesic effects of loperamide in bone cancer pain in mice. Pharmacol Biochem Behav 81: 114-121.
33. Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355-474.
34. Nieto FR, Cendán CM, Sánchez-Fernández C, Cobos EJ, Entrena JM, Tejada MA, Zamanillo D, Vela JM, and Baeyens JM (2012) Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice. J Pain 13:1107-1121.
35. Ocaña M, Del Pozo E, Barrios M, and Baeyens JM (1995) Subgroups among muopioid receptor agonists distinguished by ATP-sensitive K1 channel-acting drugs. Br J Pharmacol 114:1296-1302.
36. Olesen AE, Upton R, Foster DJ, Staahl C, Christrup LL, Arendt-Nielsen L, and Drewes AM (2010) A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia. Clin Pharmacokinet 49:817-827.
37. Pan YX, Mei J, Xu J, Wan BL, Zuckerman A, and Pasternak GW (1998) Cloning and characterization of a mouse sigma1 receptor. J Neurochem 70:2279-2285.
38. Parenti C, Turnaturi R, Aricò G, Marrazzo A, Prezzavento O, Ronsisvalle S, Scoto GM, Ronsisvalle G, and Pasquinucci L (2012) Antinociceptive profile of LP1, a nonpeptide multitarget opioid ligand. Life Sci 90:957-961.
39. Pasternak GW (2004) Multiple opiate receptors: déjà vu all over again. Neuropharmacology 47 (Suppl 1):312-323.
40. Pasternak G and Pan YX (2011) Mu opioid receptors in pain management. Acta Anaesthesiol Taiwan 49:21-25.
41. Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, and Raffa RB, et al. (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8:287-313.
42. Raehal KM, Schmid CL, Groer CE, and Bohn LM (2011) Functional selectivity at the m-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev 63:1001-1019.
43. Ringkamp M and Raja SN (2012) Dissecting the relative contribution of central versus peripheral opioid analgesia: are the analgesic and adverse effects of opioids inseparable? Eur J Pain 16:621-623.
44. Romero L, Zamanillo D, Nadal X, Sánchez-Arroyos R, Rivera-Arconada I, Dordal A, Montero A, Muro A, Bura A, and Segalés C, et al. (2012) Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization. Br J Pharmacol 166:2289-2306.
45. Sánchez-Fernández C, Nieto FR, González-Cano R, Artacho-Cordón A, Romero L, Montilla-García A, Zamanillo D, Baeyens JM, Entrena JM, and Cobos EJ (2013) Potentiation of morphine-induced mechanical antinociception by receptor inhibition: role of peripheral receptors. Neuropharmacology 70:348-358.
46. Schäfer M (2010) Opioids in pain medicine, in Guide to Pain Management in Low- Resources Setting (Kopf A and Patel NB, eds) pp 39-45, IASP Press, Seattle.
47. Sehgal N, Smith HS, and Manchikanti L (2011) Peripherally acting opioids and clinical implications for pain control. Pain Physician 14:249-258.
48. Sevostianova N, Danysz W, and Bespalov AY (2005) Analgesic effects of morphine and loperamide in the rat formalin test: interactions with NMDA receptor antagonists. Eur J Pharmacol 525:83-90.
49. Shannon HE and Lutz EA (2002) Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats. Neuropharmacology 42:253-261.
50. Smith MT (2008) Differences between and combinations of opioids re-visited. Curr Opin Anaesthesiol 21:596-601.
51. Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB, and Israel RJ (2008) Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 358:2332-2343.
52. Vidal-Torres A, de la Puente B, Rocasalbas M, Touriño C, Andreea Bura S, Fernández- Pastor B, Romero L, Codony X, Zamanillo D, and Buschmann H, et al. (2013) Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effects. Eur J Pharmacol 711:63-72.
53. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, and Rice KC (1990) Sigma receptors: biology and function. Pharmacol Rev 42:355-402.
54. Wegert S, Ossipov MH, Nichols ML, Bian D, Vanderah TW, Malan TP, Jr, and Porreca F (1997) Differential activities of intrathecal MK-801 or morphine to alter responses to thermal and mechanical stimuli in normal or nerve-injured rats. Pain 71:57-64.
55. Yassen A, Olofsen E, Dahan A, and Danhof M (2005) Pharmacokinetic- pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther 313:1136-1149.
56. Zamanillo D, Romero L, Merlos M, and Vela JM (2013) Sigma 1 receptor: A new therapeutic target for pain. Eur J Pharmacol 716:78-93 10.1016/j.ejphar. 2013.01.068.
57. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109-110.